New guidelines have been developed to treat recently diagnosed multiple myeloma in patients who are not participating in clinical trials.
After expedited review, the FDA okays the first generic version of Doxil (doxorubicin hydrochloride liposome injection), now in short supply.
A fluorescent assay has been developed that may help predict which patients with multiple myeloma will respond better to certain treatments. The test can detect those cells that survive chemotherapy and are responsible for disease relapse.
A recent study investigated the safety, efficacy, and maximum tolerated dose of pomalidomide for patients with multiple myeloma whose disease relapsed after treatments with other drugs such as bortezomib and lenalidomide.
A new oral agent is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a recently reported, multicenter, phase II study.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
Vincristine is a vinca alkaloid indicated for the treatment of certain cancers, and may also be used in some combination therapies.
Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient's unexplained neurologic symptoms.
A study showed durable responses to and acceptable tolerability for carfilzomib (Kyprolis), okayed last month for advanced multiple myeloma.
Carfilzomib is approved for people who have been treated with at least two other therapies.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|